Developer docs
API playgroundTry for free, no card

Search company profiles

CathRx

Full company profile

uuid0003szc

Namestring
CathRx
Legal namestring
CathRx Ltd
Websiteurl
cathrx.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

CathRx Ltd is an Australian privately-held medical device company headquartered in Rydalmere, Sydney, that develops and manufactures electrophysiology (EP) catheters for the diagnosis and treatment of cardiac arrhythmias, principally atrial fibrillation. The company's product platform is built on a modular catheter architecture spanning catheter tubes, steering stylets, control handles, and full catheter assemblies, with the Khelix diagnostic catheter system supporting over 300 configuration combinations across fixed, steerable, and loop variants. The ElectroPulse Pulsed Field Ablation (PFA) System extends the platform into therapeutic ablation using 8F catheters, a 2800V generator, real-time tissue contact sensing, and a dual-use design that combines mapping and ablation in a single catheter.

CathRx monetises through direct enterprise field sales of the Khelix diagnostic system to hospitals and electrophysiology labs across seven approved regulatory markets (Australia TGA, New Zealand MedSafe, Europe CE Mark, USA FDA 510K, Korea MFDS, Taiwan TFDA, Thailand Thai FDA), with commercial sales commencing in 2024 from a low-volume Rydalmere pilot facility and high-volume production scheduled to scale at contract manufacturer New Deantronics in Chiayi, Taiwan from Q4 2025. The ElectroPulse PFA System is currently investigational and undergoing multi-centre pivotal clinical trials (FIH results reported November 2025, pivotal trial commenced December 2025) with future commercialisation contingent on regulatory approval. The company operates under ISO 13485:2016, MDSAP, and EC-Full Quality Assurance System certifications and holds an extensive granted patent portfolio across the USA, Europe, Japan, China, Germany, and Australia.

Customer segments are electrophysiologists and cardiac care hospitals performing arrhythmia diagnosis and atrial fibrillation ablation. CathRx's go-to-market is a direct enterprise sales motion supported by ISO-compliant manufacturing, regulatory affairs infrastructure, and senior commercial leadership with prior experience at Boston Scientific, Biosense Webster (J&J), Acutus, Biotronik, and Galaxy Medical. Revenue is not publicly disclosed; the company's funding to date includes an MTPConnect Medical Research Future Fund grant (AUD 711,590 lead tranche, June 2025) as part of broader Australian government medtech backing.

Short descriptiontext

CathRx is a Sydney-based medical device company developing and commercialising modular electrophysiology catheters, including the Khelix diagnostic system and the investigational ElectroPulse pulsed-field ablation system, sold directly to hospitals and EP labs globally for atrial fibrillation diagnosis and treatment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
electrophysiology catheters, cardiac ablation devices, pulsed field ablation systems, atrial fibrillation treatment, cardiac mapping catheters
Industry2 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Electrophysiology Catheters
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Khelix Diagnostic Catheters Sales
TypeHardware Sales
Description

Commercial sales of the Khelix diagnostic catheter system, including loop, steerable, and fixed EP catheters. Sales commenced in 2024 from the pilot manufacturing facility in Sydney, Australia. Larger-scale production from Taiwan facility planned for Q4 2025.

cathrx.com
2ElectroPulse PFA System (Investigational)
TypeHardware Sales
Description

The ElectroPulse PFA System is currently an investigational device not available for sale. It is undergoing multi-centre pivotal clinical trials as of late 2025. Future revenue expected upon regulatory approval.

cathrx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1No public pricing available
ModelOtherBilling cadencePay-as-you-go
Notes

Product pricing is not publicly disclosed. Website states prices are in AUD and exclusive of GST. Contact-based pricing for medical device sales.

cathrx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Khelix
Description

Khelix is a diagnostic electrophysiology catheter brand offering loop, steerable, and fixed catheter configurations. The catheters are designed for precision and control in EP diagnostics and procedures.

cathrx.com
+1 more record
Core offering1 text field

CathRx designs, develops, and manufactures modular electrophysiology (EP) catheters used by cardiac specialists to diagnose and treat cardiac arrhythmias, particularly atrial fibrillation. Its commercialized Khelix diagnostic catheter system offers loop, steerable, and fixed catheter variants configurable in over 300 ways. The investigational ElectroPulse pulsed-field ablation (PFA) system adds therapeutic ablation capability using 8F catheters and a 2800V generator for non-thermal tissue-selective ablation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 8F catheter size among the smallest on the market for reduced perforation risk
+3 more records
Product overview1 text field

CathRx offers two core product lines: the Khelix Diagnostic Electrophysiology Catheter system (commercially available) and the ElectroPulse Pulse Field Ablation (PFA) System (investigational). The Khelix system includes Fixed, Steerable, and Loop catheter variants designed for cardiac mapping and arrhythmia diagnosis, offering over 300 configuration options. The ElectroPulse PFA System is a therapeutic ablation platform consisting of 8F ablation catheters (Variable Loop, Linear Tip, and Big Eye Focal variants) with a 2800V generator, designed for both diagnostic and therapeutic functions in atrial fibrillation treatment. The Khelix diagnostic platform serves as the proven cost-effective foundation for the ElectroPulse PFA catheters, enabling shared manufacturing efficiency.

Product and service5 records
1Khelix Diagnostic Electrophysiology Catheter System
CategoryElectrophysiology diagnostic catheters
Description

Modular diagnostic electrophysiology catheter system with more than 300 configuration options for cardiac mapping and arrhythmia diagnosis, available in three variants (Fixed, Steerable, and Loop) for electrophysiologists and hospitals performing EP procedures.

2Khelix Loop EP Catheter
CategoryElectrophysiology diagnostic catheters
Description

Loop electrophysiology catheter with a distal loop containing platinum-iridium electrodes for left atrium mapping, available in variable or fixed loop diameters (15-25mm) and equipped with a Loop Release safety mechanism for disentanglement.

3Khelix Steerable EP Catheter
CategoryElectrophysiology diagnostic catheters
Description

Unidirectional steerable electrophysiology catheter controlled by push/pull knob, available as single-use or reposable (up to 10 uses for certain variants) in various curve shapes and electrode configurations (4-20 electrodes).

4Khelix Fixed EP Catheter
CategoryElectrophysiology diagnostic catheters
Description

Fixed electrophysiology catheter with a catheter shaft containing platinum-iridium electrode array for stimulation and recording, available in multiple electrode configurations (4-6 electrodes) and curve types.

5ElectroPulse PFA System
CategoryCardiac ablation catheters
Description

Pulsed Field Ablation (PFA) system for therapeutic treatment of atrial fibrillation, featuring 8F catheter designs, a 2800V generator, real-time tissue contact sensing, heartbeat synchronization, and dual-use diagnostic and therapeutic capability. Currently an investigational device undergoing pivotal clinical trials and not yet commercially available.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

New Deantronics is CathRx's contract manufacturing partner located in Chiayi, Taiwan. They handle high-volume production of CathRx's catheter products, while CathRx's Rydalmere facility handles low-volume in-house production. Scale-up to the Taiwan facility is planned for Q4 2025 to support larger customer orders.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Boston Scientific acquired Farapulse, one of the leading commercialized pulsed field ablation (PFA) systems for atrial fibrillation. As a diversified cardiovascular medtech giant with deep EP infrastructure (including the Rhythmia mapping system), it competes directly with CathRx across both EP diagnostics and PFA therapy, and represents the gold standard commercial benchmark in the space.

2Johnson & Johnson (Biosense Webster)
TypeBroad incumbent
Description

Biosense Webster, J&J's electrophysiology business, is the global EP market leader with the Carto 3D mapping system and Varipulse PFA catheter. It is the dominant incumbent CathRx competes against in cardiac EP labs worldwide, with unmatched sales coverage and clinical relationships.

TypeBroad incumbent
Description

Medtronic's cardiac rhythm management franchise includes the PulseSelect PFA system (FDA-approved for AF) and the Affera mapping-and-ablation platform. As one of the four major incumbents in EP, it directly competes with CathRx's planned PFA offering and brings substantial clinical evidence and hospital relationships.

4Abbott
TypeBroad incumbent
Description

Abbott's electrophysiology portfolio includes the TactiFlex Ablation Catheter and the EnSite X 3D mapping system, with PFA development underway. It competes with CathRx across both EP diagnostics and ablation therapy, and is one of the four core incumbents shaping the PFA competitive landscape.

5Acutus Medical
TypeDirect peer
Description

Acutus Medical developed EP mapping catheters and ablation technologies for arrhythmia treatment, with a comparable niche-player profile to CathRx. Its AcQMap system and prior PFA efforts make it a directly comparable emerging EP player competing for similar hospital customers and PFA market entry.

TypeDirect peer
Description

Galaxy Medical develops pulsed electric field (PEF) ablation systems including the CENTAURI and ECLIPSE platforms, focusing on cardiac arrhythmia treatment. It is a direct emerging peer to CathRx in the PFA space, and notably Galaxy Medical's VP-level talent overlaps with CathRx's Head of Commercial.

TypeDirect peer
Description

Biotronik manufactures electrophysiology catheters and cardiac rhythm management devices, including diagnostic and ablation catheters for arrhythmia treatment. It is a directly comparable EP-focused mid-sized player competing in similar hospital accounts and serving electrophysiologists globally.

8MicroPort Scientific
TypeDirect peer
Description

MicroPort's cardiac rhythm management business develops and commercializes electrophysiology catheters and ablation technologies, including PFA systems, in competition with global EP players. It is comparable to CathRx as a global EP/PFA catheter developer with similar customer base and product categories.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CathRx

Electrophysiology Catheterscathrx.com

CathRx is a Sydney-based medical device company developing and commercialising modular electrophysiology catheters, including the Khelix diagnostic system and the investigational ElectroPulse pulsed-field ablation system, sold directly to hospitals and EP labs globally for atrial fibrillation diagnosis and treatment.

What CathRx does

CathRx Ltd is an Australian privately-held medical device company headquartered in Rydalmere, Sydney, that develops and manufactures electrophysiology (EP) catheters for the diagnosis and treatment of cardiac arrhythmias, principally atrial fibrillation. The company's product platform is built on a modular catheter architecture spanning catheter tubes, steering stylets, control handles, and full catheter assemblies, with the Khelix diagnostic catheter system supporting over 300 configuration combinations across fixed, steerable, and loop variants. The ElectroPulse Pulsed Field Ablation (PFA) System extends the platform into therapeutic ablation using 8F catheters, a 2800V generator, real-time tissue contact sensing, and a dual-use design that combines mapping and ablation in a single catheter.

CathRx monetises through direct enterprise field sales of the Khelix diagnostic system to hospitals and electrophysiology labs across seven approved regulatory markets (Australia TGA, New Zealand MedSafe, Europe CE Mark, USA FDA 510K, Korea MFDS, Taiwan TFDA, Thailand Thai FDA), with commercial sales commencing in 2024 from a low-volume Rydalmere pilot facility and high-volume production scheduled to scale at contract manufacturer New Deantronics in Chiayi, Taiwan from Q4 2025. The ElectroPulse PFA System is currently investigational and undergoing multi-centre pivotal clinical trials (FIH results reported November 2025, pivotal trial commenced December 2025) with future commercialisation contingent on regulatory approval. The company operates under ISO 13485:2016, MDSAP, and EC-Full Quality Assurance System certifications and holds an extensive granted patent portfolio across the USA, Europe, Japan, China, Germany, and Australia.

Customer segments are electrophysiologists and cardiac care hospitals performing arrhythmia diagnosis and atrial fibrillation ablation. CathRx's go-to-market is a direct enterprise sales motion supported by ISO-compliant manufacturing, regulatory affairs infrastructure, and senior commercial leadership with prior experience at Boston Scientific, Biosense Webster (J&J), Acutus, Biotronik, and Galaxy Medical. Revenue is not publicly disclosed; the company's funding to date includes an MTPConnect Medical Research Future Fund grant (AUD 711,590 lead tranche, June 2025) as part of broader Australian government medtech backing.

CathRx firmographics

Firmographics
Name
CathRx
Legal name
CathRx Ltd
Website
https://cathrx.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
CathRx is a Sydney-based medical device company developing and commercialising modular electrophysiology catheters, including the Khelix diagnostic system and the investigational ElectroPulse pulsed-field ablation system, sold directly to hospitals and EP labs globally for atrial fibrillation diagnosis and treatment.
Ownership category
akta.pro rank

CathRx industry classification

Industry
Product category
Electrophysiology Catheters
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)

Keywords

  • Electrophysiology catheters
  • Cardiac ablation devices
  • Pulsed field ablation systems
  • Atrial fibrillation treatment
  • Cardiac mapping catheters

Where CathRx is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

CathRx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Khelix Diagnostic Catheters Sales: Commercial sales of the Khelix diagnostic catheter system, including loop, steerable, and fixed EP catheters. Sales commenced in 2024 from the pilot manufacturing facility in Sydney, Australia. Larger-scale production from Taiwan facility planned for Q4 2025.
  2. ElectroPulse PFA System (Investigational): The ElectroPulse PFA System is currently an investigational device not available for sale. It is undergoing multi-centre pivotal clinical trials as of late 2025. Future revenue expected upon regulatory approval.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo public pricing available

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

CathRx product offering

Product offering

Core offering

CathRx designs, develops, and manufactures modular electrophysiology (EP) catheters used by cardiac specialists to diagnose and treat cardiac arrhythmias, particularly atrial fibrillation. Its commercialized Khelix diagnostic catheter system offers loop, steerable, and fixed catheter variants configurable in over 300 ways. The investigational ElectroPulse pulsed-field ablation (PFA) system adds therapeutic ablation capability using 8F catheters and a 2800V generator for non-thermal tissue-selective ablation.

Product overview

CathRx offers two core product lines: the Khelix Diagnostic Electrophysiology Catheter system (commercially available) and the ElectroPulse Pulse Field Ablation (PFA) System (investigational). The Khelix system includes Fixed, Steerable, and Loop catheter variants designed for cardiac mapping and arrhythmia diagnosis, offering over 300 configuration options. The ElectroPulse PFA System is a therapeutic ablation platform consisting of 8F ablation catheters (Variable Loop, Linear Tip, and Big Eye Focal variants) with a 2800V generator, designed for both diagnostic and therapeutic functions in atrial fibrillation treatment. The Khelix diagnostic platform serves as the proven cost-effective foundation for the ElectroPulse PFA catheters, enabling shared manufacturing efficiency.

Differentiator

Problem solved

Functional benefit

Brands

  • Khelix: Khelix is a diagnostic electrophysiology catheter brand offering loop, steerable, and fixed catheter configurations. The catheters are designed for precision and control in EP diagnostics and procedures.
  • ElectroPulse

Products and services

  • Khelix Diagnostic Electrophysiology Catheter System Modular diagnostic electrophysiology catheter system with more than 300 configuration options for cardiac mapping and arrhythmia diagnosis, available in three variants (Fixed, Steerable, and Loop) for electrophysiologists and hospitals performing EP procedures.
  • Khelix Loop EP Catheter Loop electrophysiology catheter with a distal loop containing platinum-iridium electrodes for left atrium mapping, available in variable or fixed loop diameters (15-25mm) and equipped with a Loop Release safety mechanism for disentanglement.
  • Khelix Steerable EP Catheter Unidirectional steerable electrophysiology catheter controlled by push/pull knob, available as single-use or reposable (up to 10 uses for certain variants) in various curve shapes and electrode configurations (4-20 electrodes).
  • Khelix Fixed EP Catheter Fixed electrophysiology catheter with a catheter shaft containing platinum-iridium electrode array for stimulation and recording, available in multiple electrode configurations (4-6 electrodes) and curve types.
  • ElectroPulse PFA System Pulsed Field Ablation (PFA) system for therapeutic treatment of atrial fibrillation, featuring 8F catheter designs, a 2800V generator, real-time tissue contact sensing, heartbeat synchronization, and dual-use diagnostic and therapeutic capability. Currently an investigational device undergoing pivotal clinical trials and not yet commercially available.

Quantifiable outcome

  • 8F catheter size among the smallest on the market for reduced perforation risk
  • +3 more outcomes

Companies that use CathRx

Customer profile

Segments2 records

Ideal customer profiles2 records

CathRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

CathRx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • New DeantronicscoreTechnology or IntegrationNew Deantronics is CathRx's contract manufacturing partner located in Chiayi, Taiwan. They handle high-volume production of CathRx's catheter products, while CathRx's Rydalmere facility handles low-volume in-house production. Scale-up to the Taiwan facility is planned for Q4 2025 to support larger customer orders.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

CathRx competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Boston Scientific acquired Farapulse, one of the leading commercialized pulsed field ablation (PFA) systems for atrial fibrillation. As a diversified cardiovascular medtech giant with deep EP infrastructure (including the Rhythmia mapping system), it competes directly with CathRx across both EP diagnostics and PFA therapy, and represents the gold standard commercial benchmark in the space.
  • Johnson & Johnson (Biosense Webster): Biosense Webster, J&J's electrophysiology business, is the global EP market leader with the Carto 3D mapping system and Varipulse PFA catheter. It is the dominant incumbent CathRx competes against in cardiac EP labs worldwide, with unmatched sales coverage and clinical relationships.
  • Medtronic: Medtronic's cardiac rhythm management franchise includes the PulseSelect PFA system (FDA-approved for AF) and the Affera mapping-and-ablation platform. As one of the four major incumbents in EP, it directly competes with CathRx's planned PFA offering and brings substantial clinical evidence and hospital relationships.
  • Abbott: Abbott's electrophysiology portfolio includes the TactiFlex Ablation Catheter and the EnSite X 3D mapping system, with PFA development underway. It competes with CathRx across both EP diagnostics and ablation therapy, and is one of the four core incumbents shaping the PFA competitive landscape.

Direct peers

  • Acutus Medical: Acutus Medical developed EP mapping catheters and ablation technologies for arrhythmia treatment, with a comparable niche-player profile to CathRx. Its AcQMap system and prior PFA efforts make it a directly comparable emerging EP player competing for similar hospital customers and PFA market entry.
  • Galaxy Medical: Galaxy Medical develops pulsed electric field (PEF) ablation systems including the CENTAURI and ECLIPSE platforms, focusing on cardiac arrhythmia treatment. It is a direct emerging peer to CathRx in the PFA space, and notably Galaxy Medical's VP-level talent overlaps with CathRx's Head of Commercial.
  • Biotronik: Biotronik manufactures electrophysiology catheters and cardiac rhythm management devices, including diagnostic and ablation catheters for arrhythmia treatment. It is a directly comparable EP-focused mid-sized player competing in similar hospital accounts and serving electrophysiologists globally.
  • MicroPort Scientific: MicroPort's cardiac rhythm management business develops and commercializes electrophysiology catheters and ablation technologies, including PFA systems, in competition with global EP players. It is comparable to CathRx as a global EP/PFA catheter developer with similar customer base and product categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks2 records

Key highlights6 records

Customer concentration

CathRx social profiles

Digital presence

CathRx compliance and trust

Trust signal

Compliance5 records

CathRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CathRx leadership team

Management profile

Number of profiles

Profiles9 records

CathRx subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CathRx funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CathRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CathRx

What does CathRx do?

CathRx designs, develops, and manufactures modular electrophysiology (EP) catheters used by cardiac specialists to diagnose and treat cardiac arrhythmias, particularly atrial fibrillation. Its commercialized Khelix diagnostic catheter system offers loop, steerable, and fixed catheter variants configurable in over 300 ways. The investigational ElectroPulse pulsed-field ablation (PFA) system adds therapeutic ablation capability using 8F catheters and a 2800V generator for non-thermal tissue-selective ablation.

Is CathRx a public or private company?

CathRx is a private company. It is classified as unknown and is currently operating.

When was CathRx founded?

CathRx was founded in 1999. It employs 11 to 50 people.

Where is CathRx based?

CathRx is headquartered in Sydney, Australia, in the Oceania region.

How does CathRx make money?

Two revenue lines are on record. Khelix Diagnostic Catheters Sales are the primary driver. The others are electroPulse PFA System (Investigational).

Who are CathRx's main competitors?

Broad incumbents on record are Boston Scientific, Johnson & Johnson (Biosense Webster), Medtronic and Abbott. Direct peers are Acutus Medical, Galaxy Medical, Biotronik and MicroPort Scientific.

Does CathRx have an API?

No public API is recorded for CathRx.

What industry is CathRx in?

CathRx's product category is Electrophysiology Catheters. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales